AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1357701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2866117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 57
Study 2866117 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen-sodium
Number of subjects: 57
Study 31136450 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming-based dexterity training (30 minutes, twice a week for 4 weeks)
Number of subjects: 10
Study 29563377 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (standard usage)
Number of subjects: 117
Study 29563377 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (with heparin added in decreasing amounts)
Number of subjects: 117
Study 29563377 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin (additional bolus)
Number of subjects: 117
Study 29563377 — intervention group
Group type: COMPARATOR
Intervention: Heparin (bolus)
Number of subjects: 117
Study 26590384 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure <140/90 mmHg
Number of subjects: 0
Study 26590384 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure <130/80 mmHg
Number of subjects: 0
Study 26590384 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean on-treatment SBP 130-139 mmHg or DBP 80-89 mmHg
Number of subjects: 0
Study 26590384 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean on-treatment SBP <130 mmHg or DBP <80 mmHg
Number of subjects: 0
Study 24237691 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine HCl (10.8 mg)
Number of subjects: 40
Study 24237691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21972179 — intervention group
Group type: EXPERIMENTAL
Intervention: Controllable painful electric skin stimuli
Number of subjects: 64
Study 21972179 — intervention group
Group type: COMPARATOR
Intervention: Uncontrollable painful electric skin stimuli
Number of subjects: 64
Study 20042310 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant cetuximab with capecitabine-based chemoradiotherapy (CRT)
Number of subjects: 37
Study 20042310 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant cetuximab with capecitabine-based CRT
Number of subjects: 37
Study 18568228 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical treatment
Number of subjects: 30
Study 18568228 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting
Number of subjects: 30
Study 18568228 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical treatment - 0.4 mm beads
Number of subjects: 30
Study 18568228 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical treatment - 0.6 mm beads
Number of subjects: 30
Study 18568228 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical/mechanical treatment - 0.4 mm beads
Number of subjects: 30
Study 18568228 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical/mechanical treatment - 0.6 mm beads
Number of subjects: 30
Study 16238901 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intravenous test dose of paclitaxel or docetaxel
Number of subjects: 218
Study 16238901 — intervention group
Group type: COMPARATOR
Intervention: Full dose of paclitaxel or docetaxel without a test dose
Number of subjects: 218
Study 11908576 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness program (n = 58)
Number of subjects: 143
Study 11908576 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training (n = 56)
Number of subjects: 143
Study 11908576 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group, n = 29)
Number of subjects: 143
Study 9923505 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF/triclosan/Gantrez dentifrice slurry (1 ml mixed with 10 ml tap water)
Number of subjects: 10
Study 9923505 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF/triclosan/Gantrez mouthrinse (10 ml)
Number of subjects: 10
Study 9923505 — intervention group
Group type: COMPARATOR
Intervention: NaF mouthrinse (10 ml)
Number of subjects: 10
Study 7579056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine monotherapy (CsA)
Number of subjects: 122
Study 7579056 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of Pred in CsA group
Number of subjects: 122
Study 7579056 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with Pred
Number of subjects: 122
Study 7579056 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (Pred) use
Number of subjects: 122
Study 7579056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) use
Number of subjects: 122
Study 2284832 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing containing anthralin (0.02 to 0.20 mg/cm2)
Number of subjects: 0
Study 2284832 — intervention group
Group type: COMPARATOR
Intervention: Short-contact therapy with anthralin alone
Number of subjects: 0
Study 500259 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6
Study 500259 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 6
Study 500259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31828962 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Nutritional Risk Index (GNRI)
Number of subjects: 417
Study 31627478 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily fish consumption
Number of subjects: 20670
Study 28492711 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with curcumin
Number of subjects: 0
Study 28492711 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 0
Study 25634195 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-L split-dose PEG
Number of subjects: 318
Study 25634195 — intervention group
Group type: COMPARATOR
Intervention: 2-L PEG
Number of subjects: 318
Study 23249342 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 0
Study 23249342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21136272 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG) received the CPG‐PD with special instructions, a 4‐h training, and personal feedback.
Number of subjects: 386
Study 21136272 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) did not receive the same intervention as IG.
Number of subjects: 386
Study 19305145 — intervention group
Group type: EXPERIMENTAL
Intervention: VARIVAX
Number of subjects: 507
Study 19305145 — intervention group
Group type: COMPARATOR
Intervention: M-M-R II
Number of subjects: 507
Study 17242626 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 128
Study 17242626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 15651179 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amphotericin B and fluconazole
Number of subjects: 0
Study 15651179 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinocandins in combination with triazoles
Number of subjects: 0
Study 15651179 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of echinocandin to monotherapy for aspergillosis
Number of subjects: 0
Study 12166510 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 50 mg/day
Number of subjects: 44
Study 12166510 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific antiproteinuric treatment)
Number of subjects: 44
Study 9756589 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep acupuncture treatment
Number of subjects: 104
Study 9756589 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial acupuncture treatment
Number of subjects: 104
Study 9756589 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture treatment (control group)
Number of subjects: 104
Study 9756589 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional stroke rehabilitation
Number of subjects: 104
Study 8110006 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonic ORS with citrate
Number of subjects: 107
Study 8110006 — intervention group
Group type: COMPARATOR
Intervention: Hypotonic ORS without citrate
Number of subjects: 107
Study 3276933 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous vein patching
Number of subjects: 129
Study 3276933 — intervention group
Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 129
Study 3276933 — intervention group
Group type: COMPARATOR
Intervention: Primary closure in women
Number of subjects: 129
Study 3276933 — intervention group
Group type: COMPARATOR
Intervention: Primary closure in men
Number of subjects: 129
Study 3276933 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching in men
Number of subjects: 129
Study 3276933 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching in women
Number of subjects: 129
Study 31828291 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted trivalent vaccine
Number of subjects: 200
Study 31828291 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose trivalent vaccine
Number of subjects: 200
Study 31828291 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant-hemagglutinin (rHA) quadrivalent vaccine
Number of subjects: 200
Study 31828291 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose quadrivalent vaccine
Number of subjects: 200
Study 31828291 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced vaccines
Number of subjects: 200
Study 29303039 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 255
Study 28743491 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical score based on liver stiffness, BILCHE score, type of hepatectomy, and presence of varices
Number of subjects: 340
Study 25061062 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of 4 mL of 1% lignocaine
Number of subjects: 42
Study 25061062 — intervention group
Group type: COMPARATOR
Intervention: Repetitive injection of 4 mL of 1% lignocaine twice a week for 2 weeks
Number of subjects: 42
Study 24012360 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-row technique
Number of subjects: 90
Study 24012360 — intervention group
Group type: COMPARATOR
Intervention: Double-row suture bridge technique
Number of subjects: 90
Study 20805274 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 microg/day calcitriol
Number of subjects: 34
Study 20805274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 20805274 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol and Placebo
Number of subjects: 34
Study 17976882 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10-20 mg/day for 12 weeks
Number of subjects: 100
Study 17976882 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (n=45; 19 males and 26 females)
Number of subjects: 100
Study 15992422 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg doxorubicin
Number of subjects: 82
Study 15992422 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy (control group)
Number of subjects: 82
Study 12851511 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hormone replacement therapy (2 mg daily of 17beta-estradiol plus 10 mg dydrogesterone daily for 14 days of each 28-day cycle)
Number of subjects: 75
Study 12851511 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy (50 microg daily of 17beta-estradiol plus 10 mg dydrogesterone daily for 14 days of each 28-day cycle)
Number of subjects: 75
Study 12851511 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation (control group)
Number of subjects: 75
Study 10541423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 120 mg QD
Number of subjects: 845
Study 10541423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 180 mg QD
Number of subjects: 845
Study 10541423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 845
Study 9084323 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol
Number of subjects: 0
Study 9084323 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol
Number of subjects: 0
Study 9084323 — intervention group
Group type: EXPERIMENTAL
Intervention: Both xylitol and sorbitol
Number of subjects: 0
Study 1920093 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin 0.075% cream
Number of subjects: 0
Study 1920093 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 7295487 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ)
Number of subjects: 33
Study 30844639 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy (bCBT)
Number of subjects: 302
Study 30844639 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 302
Study 28623320 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-based infant formula
Number of subjects: 0
Study 28623320 — intervention group
Group type: EXPERIMENTAL
Intervention: CSS-based infant formula
Number of subjects: 0
Study 28623320 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed infants
Number of subjects: 0
Study 25865762 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric bicuspid annuloplasty ring
Number of subjects: 16
Study 23331817 — intervention group
Group type: EXPERIMENTAL
Intervention: Single umbilical incision laparoscopic cholecystectomy
Number of subjects: 60
Study 23331817 — intervention group
Group type: COMPARATOR
Intervention: 4-port laparoscopic cholecystectomy
Number of subjects: 60
Study 21406001 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) procedure
Number of subjects: 23
Study 21406001 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 23
Study 19320663 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin three times daily before meals
Number of subjects: 40
Study 19320663 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine administered in the morning before breakfast
Number of subjects: 40
Study 17122220 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (Group L)
Number of subjects: 240
Study 17122220 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 100 microg/kg (Group K100)
Number of subjects: 240
Study 17122220 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam premedication (Group M)
Number of subjects: 240
Study 17122220 — intervention group
Group type: COMPARATOR
Intervention: Ketamine mixed with propofol (Group KP)
Number of subjects: 240
Study 17122220 — intervention group
Group type: COMPARATOR
Intervention: Ketamine administered 3 min before propofol (Group Pre)
Number of subjects: 240
Study 15500817 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 40
Study 15500817 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Number of subjects: 40
Study 15500817 — intervention group
Group type: COMPARATOR
Intervention: Programmed generalization condition
Number of subjects: 40
Study 11239727 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-session cognitive-behavioral therapy (CBT) program
Number of subjects: 229
Study 11239727 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session brief intervention
Number of subjects: 229
Study 11239727 — intervention group
Group type: COMPARATOR
Intervention: Delayed-treatment control group
Number of subjects: 229
Study 9402774 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide 50 micrograms twice daily for 6 months with programmed injection sclerotherapy
Number of subjects: 32
Study 9402774 — intervention group
Group type: COMPARATOR
Intervention: Programmed injection sclerotherapy alone
Number of subjects: 32
Study 8500239 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 804
Study 8500239 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine‐isosorbide dinitrate
Number of subjects: 804
Study 3502138 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (10 mg i.v.)
Number of subjects: 0
Study 3502138 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (2 mg i.v.)
Number of subjects: 0
Study 31628873 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided virtual surgery (stereolithographic guides)
Number of subjects: 12
Study 31628873 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (conventional guides)
Number of subjects: 12
Study 30522512 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health intervention including oral health education sessions and daily oral self-care under caregiver supervision.
Number of subjects: 520
Study 30522512 — intervention group
Group type: COMPARATOR
Intervention: Control group (children living with HIV receiving standard care).
Number of subjects: 520
Study 30522512 — intervention group
Group type: COMPARATOR
Intervention: Control group (HIV-uninfected children age-matched to the intervention group).
Number of subjects: 520
Study 27397927 — intervention group
Group type: EXPERIMENTAL
Intervention: True air purifiers
Number of subjects: 35
Study 27397927 — intervention group
Group type: COMPARATOR
Intervention: Sham air purifiers
Number of subjects: 35
Study 27397927 — intervention group
Group type: EXPERIMENTAL
Intervention: PM2.5 exposure (IQR increase of 64μg/m(3))
Number of subjects: 35
Study 27397927 — intervention group
Group type: EXPERIMENTAL
Intervention: PM2.5 exposure
Number of subjects: 35
Study 24795200 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-450/r-ombitasvir and dasabuvir with ribavirin
Number of subjects: 724
Study 24795200 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-450/r-ombitasvir and dasabuvir without ribavirin
Number of subjects: 724
Study 24795200 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-450/r-ombitasvir and dasabuvir with or without ribavirin
Number of subjects: 724
Study 22820824 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep heating therapy (DHT) via local microwave diathermy (three 30‐min sessions a week for four weeks)
Number of subjects: 54
Study 22820824 — intervention group
Group type: COMPARATOR
Intervention: Superficial heating therapy (SHT) via application of hot packs (three 30‐min sessions a week for four weeks)
Number of subjects: 54
Study 20478022 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways Advisory Service intervention
Number of subjects: 0
Study 20478022 — intervention group
Group type: COMPARATOR
Intervention: Cluster randomised controlled trial design
Number of subjects: 0
Study 17302873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracortical inhibition (ICI) during anovulatory cycles
Number of subjects: 20
Study 17302873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracortical inhibition (ICI) on day -14, -7, and 2 during anovulatory cycles
Number of subjects: 20
Study 17302873 — intervention group
Group type: COMPARATOR
Intervention: Intracortical inhibition (ICI) in ovulatory cycles
Number of subjects: 20
Study 17302873 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting motor threshold (RMT), cortical silent period (CSP), and intracortical facilitation (ICF)
Number of subjects: 20
Study 14657456 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid angioplasty and stenting with cerebral protection
Number of subjects: 80
Study 14657456 — intervention group
Group type: COMPARATOR
Intervention: Carotid angioplasty and stenting without cerebral protection
Number of subjects: 80
Study 11680556 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 205
Study 11680556 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Counseling plus Exercise (BEX)
Number of subjects: 205
Study 11680556 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Counseling plus Nicotine Gum (BNIC)
Number of subjects: 205
Study 11680556 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year follow-up
Number of subjects: 205
Study 9441728 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 0
Study 9441728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8204511 — intervention group
Group type: EXPERIMENTAL
Intervention: LOPP alternating with EVAP regimen
Number of subjects: 160
Study 8204511 — intervention group
Group type: COMPARATOR
Intervention: LOPP/EVA hybrid regimen
Number of subjects: 160
Study 2455170 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose clonidine (0.075 mg per day)
Number of subjects: 28
Study 2455170 — intervention group
Group type: COMPARATOR
Intervention: Control group (nontreated)
Number of subjects: 28
Study 28355957 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted state
Number of subjects: 29
Study 28355957 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed state
Number of subjects: 29
Study 28355957 — intervention group
Group type: COMPARATOR
Intervention: Satiated (fed) state
Number of subjects: 29
Study 27446961 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based self-management program
Number of subjects: 70
Study 27446961 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 70
Study 24952581 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy exercises
Number of subjects: 130
Study 24952581 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational medical assistance
Number of subjects: 130
Study 24952581 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy exercises and occupational medical assistance
Number of subjects: 130
Study 24952581 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 130
Study 23185342 — intervention group
Group type: EXPERIMENTAL
Intervention: Single re-exposition to the conditioned stimulus (CS)
Number of subjects: 26
Study 23185342 — intervention group
Group type: COMPARATOR
Intervention: Four re-expositions to the conditioned stimulus (CS)
Number of subjects: 26
Study 23185342 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation of taking an immunosuppressant
Number of subjects: 26
Study 21095277 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25OHD) concentration
Number of subjects: 40
Study 21095277 — intervention group
Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire physical limitation domain score
Number of subjects: 40
Study 18454426 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 80
Study 18454426 — intervention group
Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 80
Study 15985509 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at the Quchi (LI11) acupoint thrice weekly for 1 month
Number of subjects: 40